使用生物药物减少长期使用皮质类固醇在Pyoderma Gangrenosum:来自两个中心的现实世界的证据
R Cascio Ingurgio1,2, A Alfano1,2, L Gargiulo1,2
1Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
The Australasian journal of dermatology
|May 27, 2025
概括
系统性皮质类固醇可提供快速初始愈合的皮质性性 (PG),但生物疗法显示出优越的长期有效性和持续改善在管理这个具有挑战性的炎症性皮肤疾病.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性皮肤病 (PG) 是一种罕见的,严重的,经常使人衰弱的炎症性皮肤病.
- 目前的治疗方法,如皮质类固醇,具有显著的长期风险,需要探索替代疗法.
- 由于其有针对性的机制,生物药物代表了管理PG的有希望的途径.
研究的目的:
- 为了比较生物疗法与系统性皮质类固醇的长期疗效,在患有皮质性瘤的患者中.
- 为了评估长期的愈和再上皮质化率.
- 为持续的PG管理确定最佳的治疗策略.
主要方法:
- 在两个国际中心对15名白皮病病患进行了回顾性分析.
- 患者被分为两组:生物疗法 (n=8) 和系统性皮质类固醇 (n=7).
- 在多个时间点评估了愈的结果:第16周,第28-32周和第54周.
主要成果:
- 系统性皮质类固醇在第16周显示出更快的初始减少和重新表皮化.
- 用生物疗法治疗的患者在长期内表现出愈合的逐渐但持续改善.
- 与皮质类固醇相比,生物药物在持续控制疾病方面显示出有利的趋势.
结论:
- 虽然皮质类固醇在皮肤质性病中提供了快速的初始益处,但它们的长期使用受到潜在的不良影响的限制.
- 生物疗法表现出逐步和持续的疗效,在PG的长期管理中建立了重要的治疗作用.
- 这项研究支持考虑使用生物药物来实现性皮肤炎的持久缓解.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:29Inflammatory Bowel Disease IV: Pharmacological Management
205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
205
01:26COPD: Management Using Bronchodilators and Corticosteroids
331
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
331
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
399
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
399